NewAmsterdam Pharma Company N.V.
- Open
- 25.68
- Day high
- 25.82
- Day low
- 25.21
- Prev close
- 25.59
- Volume
- 42K
- Mkt cap
- $3.1B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 4.8
- P/S
- 429.6
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$7.8M over the last 3 months (0 open-market buys, 6 sales)
- 🏛Institutions accumulating (13F)
NewAmsterdam Pharma Company N.V. (NAMS) is a Healthcare company listed on NASDAQ. The stock is up 3% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 6 sales (SEC Form 4). Drillr has 1 published research article covering NAMS.
NewAmsterdam Pharma Company N.V. (NAMS) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
NAMS earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 5, 2026 | $-0.48 | $-0.52 | -7.9% | $4M | +30.7% |
| May 7, 2026 | $-0.46 | $-0.40 | +13.0% | $3M | +72.0% |
| Feb 18, 2026 | $-0.40 | $-0.63 | -57.5% | $32000 | -96.5% |
| Nov 5, 2025 | $-0.38 | $-0.41 | -7.9% | $348000 | -85.5% |
| May 8, 2025 | $-0.45 | $-0.49 | -8.9% | $3M | +121.1% |
| Feb 26, 2025 | $-0.48 | $-0.95 | -97.9% | $13M | +653.3% |
| Mar 29, 2024 | $-0.60 | $-0.57 | +5.5% | $2M | — |
| Jun 30, 2023 | $-0.44 | $-0.52 | -17.2% | $9M | — |
| Mar 31, 2023 | $-0.61 | $-2.37 | -289.0% | $1M | — |
| Oct 18, 2022 | — | $-2.14 | — | $5M | — |
NAMS insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 25, 2026 | Kastelein Johannes Jacob Pieterdirector, officer: Chief Scientific Officer | Sell | 125,000 | $26.91 |
| Aug 25, 2026 | Kastelein Johannes Jacob Pieterdirector, officer: Chief Scientific Officer | Option | 125,000 | — |
| Jul 22, 2026 | Kooij Louise Frederikaofficer: Chief Accounting Officer | Sell | 2,915 | $31.71 |
| Jul 22, 2026 | Kooij Louise Frederikaofficer: Chief Accounting Officer | Option | 25,000 | $11.90 |
| Jul 22, 2026 | Kooij Louise Frederikaofficer: Chief Accounting Officer | Option | 80,000 | $11.17 |
| Jul 22, 2026 | Kooij Louise Frederikaofficer: Chief Accounting Officer | Sell | 70,200 | $29.96 |
| Jul 22, 2026 | Kooij Louise Frederikaofficer: Chief Accounting Officer | Sell | 31,885 | $31.05 |
| Jun 24, 2026 | Kooij Louise Frederikaofficer: Chief Accounting Officer | Option | 15,000 | $11.90 |
| Jun 24, 2026 | Kooij Louise Frederikaofficer: Chief Accounting Officer | Sell | 39,700 | $30.20 |
| Jun 24, 2026 | Kooij Louise Frederikaofficer: Chief Accounting Officer | Sell | 300 | $30.73 |
| Jun 24, 2026 | Kooij Louise Frederikaofficer: Chief Accounting Officer | Option | 25,000 | $10.90 |
| May 27, 2026 | Kooij Louise Frederikaofficer: Chief Accounting Officer | Sell | 65,000 | $35.69 |
| May 27, 2026 | Kooij Louise Frederikaofficer: Chief Accounting Officer | Option | 60,000 | $10.00 |
| May 27, 2026 | Kooij Louise Frederikaofficer: Chief Accounting Officer | Option | 5,000 | $10.90 |
| Mar 12, 2026 | LANGE LOUIS Gdirector | Sell | 446 | $31.23 |
Source: NAMS SEC Form 4 filings, latest Aug 25, 2026. For informational purposes only — not investment advice.
See the full NAMS insider & 13F page →NewAmsterdam Pharma Company N.V. company profile
Overview
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Naarden, the Netherlands. The company went public in February 2021 and focuses on developing innovative treatments for metabolic diseases, particularly cardiovascular conditions related to cholesterol management. NewAmsterdam's primary focus is advancing its lead drug candidate through clinical trials to address unmet medical needs in cholesterol treatment and cardiovascular disease prevention.
Business
NewAmsterdam Pharma operates in the biotechnology sector within the broader healthcare industry, specifically focusing on developing treatments for metabolic diseases. The company's core product is obicetrapib, an investigational drug that represents a novel approach to cholesterol management. Obicetrapib is designed as a selective inhibitor of Cholesteryl Ester Transfer Protein (CETP). To understand this mechanism, it's important to know that cholesterol travels through the bloodstream in different forms - primarily low-density lipoprotein cholesterol (LDL-C, often called "bad cholesterol") and high-density lipoprotein cholesterol (HDL-C, or "good cholesterol"). CETP is a protein that transfers cholesterol between these lipoproteins, and by inhibiting this protein, obicetrapib aims to reduce harmful LDL-C levels while simultaneously increasing beneficial HDL-C levels. This dual action is significant because most existing cholesterol medications, such as statins, primarily focus on reducing LDL cholesterol but don't substantially raise HDL cholesterol. The company's approach targets patients with metabolic diseases, particularly those at risk for cardiovascular events who may benefit from this combined cholesterol-modifying effect. Clinical trials have demonstrated obicetrapib's ability to achieve these dual cholesterol effects, positioning it as a potential complementary or alternative treatment to existing therapies. The company operates as a single-segment business entirely focused on this drug development program, with all resources dedicated to advancing obicetrapib through clinical trials and regulatory processes.
Revenue model
As a clinical-stage biopharmaceutical company, NewAmsterdam currently generates minimal revenue and operates primarily on a research and development model funded by investor capital. The company's limited revenue of approximately $46 million in 2024 likely comes from licensing agreements, milestone payments, or collaboration arrangements related to its drug development program, rather than product sales. The company's primary business model centers on developing obicetrapib through clinical trials with the ultimate goal of obtaining regulatory approval and commercializing the drug. Once approved, NewAmsterdam would generate revenue through direct product sales to healthcare providers, hospitals, and pharmacies, or through licensing agreements with larger pharmaceutical companies for distribution and marketing. Several factors could significantly impact the company's future profitability. Positive clinical trial results demonstrating obicetrapib's efficacy and safety would increase the drug's commercial potential and attract partnership opportunities with major pharmaceutical companies. Conversely, negative trial results or regulatory setbacks could substantially reduce the company's value proposition. The competitive landscape in cholesterol management, dominated by established drugs like statins and newer PCSK9 inhibitors, will influence pricing power and market penetration. Regulatory approval timelines and requirements represent another critical factor, as extended development periods increase costs and delay revenue generation. The company's ability to secure strategic partnerships or licensing deals could provide both funding and commercial expertise, while manufacturing scale-up costs and market access challenges will impact margins once the drug reaches commercialization. Healthcare reimbursement policies and the drug's position in treatment guidelines will ultimately determine its commercial success and pricing sustainability.
Competitive moat
NewAmsterdam Pharma's competitive moat is currently limited and primarily dependent on the clinical success and regulatory approval of obicetrapib. The company's main competitive advantage lies in its novel mechanism of action through CETP inhibition, which differentiates it from existing cholesterol treatments like statins and PCSK9 inhibitors. This unique approach to simultaneously reducing LDL cholesterol while raising HDL cholesterol could provide a distinct therapeutic profile if clinical trials continue to demonstrate efficacy and safety. However, the company's moat is inherently fragile as a single-asset, clinical-stage biotechnology company. The CETP inhibition approach has a mixed historical track record, with previous attempts by larger pharmaceutical companies failing due to safety concerns or lack of efficacy. This history creates both opportunity and risk - while it may have deterred some competitors, it also raises questions about the viability of the mechanism. The company faces potential competition from established pharmaceutical giants with deeper resources and broader portfolios in cardiovascular medicine. Companies like Pfizer, Amgen, and Novartis have extensive experience in cholesterol management and could potentially develop competing CETP inhibitors or alternative mechanisms. Additionally, the cardiovascular drug market is highly competitive, with ongoing research into new approaches for lipid management and cardiovascular risk reduction. NewAmsterdam's intellectual property position around obicetrapib provides some protection, but patents eventually expire, and the company lacks the diversified pipeline that would provide multiple shots at success. The company's relatively small size and limited resources compared to Big Pharma competitors represent additional vulnerabilities in terms of clinical trial execution, regulatory navigation, and eventual commercialization capabilities.
Risks & safety
NewAmsterdam Pharma presents a mixed margin of safety profile typical of clinical-stage biotechnology companies, with strong financial liquidity but inherent business model risks. • **Liquidity position**: The company maintains excellent short-term financial health with $748 million in cash and short-term investments as of Q1 2025, providing substantial runway for operations • **Debt levels**: Minimal debt with a debt-to-equity ratio of just 0.0005, indicating virtually no financial leverage risk • **Current ratio**: Strong liquidity metrics with a current ratio of 19.98, demonstrating ability to meet short-term obligations • **Cash burn**: Significant operating cash outflows of approximately $159 million annually in 2024, suggesting roughly 4-5 years of runway at current burn rates • **Valuation concerns**: Trading at 3.06x book value with negative earnings, reflecting speculative premium typical of biotech companies • **Binary risk**: As a single-asset company, success or failure of obicetrapib clinical trials represents existential risk to the investment • **Revenue generation**: Minimal current revenue ($46 million in 2024) creates dependence on continued capital markets access or partnership deals The company's financial position provides adequate time to complete clinical development, but the inherent binary nature of drug development creates significant downside risk despite strong balance sheet metrics.
Recent development
Based on the available financial data, NewAmsterdam Pharma has been consistently advancing its clinical development program for obicetrapib over recent years. The company's revenue fluctuations suggest ongoing milestone-based collaborations or licensing activities, with 2022 showing higher revenue of $96 million compared to more modest levels in 2023-2024. The company has maintained its focus as a single-asset organization, dedicating resources entirely to obicetrapib development rather than diversifying its pipeline. This concentrated approach reflects management's confidence in the drug's potential but also represents a high-risk, high-reward strategy. The steady increase in operating losses from $78 million in 2022 to $242 million in 2024 indicates accelerated clinical trial activities and expanded development programs, typical of companies advancing through later-stage clinical trials. The company's substantial cash position improvement, growing from $439 million in 2022 to $772 million by end of 2024, suggests successful capital raising activities to fund continued development. This financial strengthening provides the resources necessary to complete pivotal clinical trials and prepare for potential regulatory submissions. The consistent negative EBITDA and operating cash flows reflect the company's current pre-revenue stage, with all expenditures focused on research and development activities rather than commercial operations.
NAMS company profile · for informational purposes only — not investment advice.
Track NAMS with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free